| |
Nano Group |
Ferro Group |
Stenting Control |
| |
PTEP, n=42 |
ITTP, n=60 |
PTEP, n=34 |
ITTP, n=60 |
PTEP, n=40 |
ITTP, n=60 |
| Age, yr |
52.8±9.6 |
51.2±10.3 |
54.2±7.9 |
50.9±8.8 |
53.2±11.5 |
52.6±6.8 |
| Males, no. of patients (%) |
40 (95.2%) |
49 (81.7%) |
32 (94.1%) |
44 (73.3%) |
39 (97.5%) |
46 (76.7%) |
| Body-mass index |
28.4±5.5 |
29.2±5.2 |
27.6±4.8 |
28.1±6.1 |
27.5±5.4 |
27.8±6.2 |
Smoking, no. (%)
• Never
• Stopped
• Current |
2 (4.8%)
11 (26.2%)
29 (69.0%) |
9 (15.0%)
5 (8.3%)
46 (76.7%) |
2 (5.9%)
15 (44.1%)
17 (50%) |
11 (18.3%)
10 (16.7%)
39 (65.0%) |
3 (7.5%)
9 (22.5%)
28 (70.0%) |
7 (11.7%)
11 (18.3%)
42 (70.0%) |
| Alcohol abusers, no. (%) |
11 (26.2%) |
29 (48.3%) |
11 (32.4%) |
37 (61.7%) |
5 (12.5%) |
25 (41.7%) |
| Diabetes, no. (%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
| Hypertension needing drugs, no. (%) |
40 (95.2%) |
52 (86.7%) |
33 (97.1%) |
49 (81.7%) |
39 (97.5%) |
54 (90.0%) |
| Treated hypertension, no. (%) |
39 (92.9%) |
44 (73.3%) |
30 (88.2%) |
44 (73.3%) |
38 (95.0%) |
45 (75.0%) |
| Hyperlipidemia needing drugs, no. (%) |
42 (100%) |
53 (88.3%) |
32 (94.1%) |
51 (85.0%) |
37 (92.5%) |
52 (86.7%) |
| Treated hyperlipidemia, no. (%) |
40 (95.2%) |
44 (73.3%) |
30 (88.2%) |
42 (70.0%) |
37 (92.5%) |
43 (71.7%) |
| Previous target vessel intervention, no. (%) |
0 (%) |
8 (13.3%) |
0 (0%) |
7 (11.7%) |
0 (%) |
10 (16.7%) |
| Previous myocardial infarction, no. (%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
CAD, no. (%)
• Single-vessel disease
• Two-vessel disease
• Three-vessel disease |
10 (23.8%)
32 (76.2%)
0 (0%) |
15 (25.0%)
39 (65.0%)
6 (10.0%) |
8 (19.0%)
26 (61.9%)
0 (0%) |
19 (31.7%)
32 (53.3%)
9 (15.0%) |
8 (20.0%)
32 (80.0%)
0 (0%) |
19 (31.7%)
32 (53.3%)
9 (15.0%) |
Stable angina, no. (%)
• CCS Class I
• CCS Class II
• CCS Class III |
42 (100%)
6 (14.3%)
36 (85.7%)
0 (0%) |
59 (98.3%)
21 (35.0%)
38 (63.3%)
0 (0%) |
34 (100%)
1 (2.9%)
33 (97.1%)
0 (0%) |
60 (100%)
24 (40.0%)
36 (60.0%)
0 (%) |
40 (100%)
8 (20.0%)
32 (80.0%)
0 (0%) |
59 (98.3%)
22 (36.7%)
37 (61.7%)
0 (0%) |
| Unstable angina, no. (%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
| Silent ischemia, no. (%) |
0 (0%) |
1 (1.7%) |
0 (0%) |
0 (0%) |
0 (0%) |
1 (1.7%) |
NYHA functional class of heart failure, no. (%)
• Class I
• Class II
• Class III
• Class IV |
0 (%)
27 (64.3%)
15 (35.7%)
0 (%) |
0 (0%)
38 (63.3%)
22 (36.7%)
0 (0%) |
0 (%)
22 (64.7%)
12 (35.3%)
0 (%) |
0 (0%)
43 (71.7%)
17 (28.3%)
0 (0%) |
0 (%)
28 (70.0%)
12 (30.0%)
0 (%) |
0 (0%)
41 (68.3%)
19 (31.7%)
0 (0%) |
| ASS, no. (%) |
42 (100%) |
60 (100%) |
34 (100%) |
60 (100%) |
40 (100%) |
60 (100%) |
| Clopidogrel, no. (%) |
41 (97.6%) |
49 (81.7%) |
34 (100%) |
52 (86.7%) |
39 (97.5%) |
59 (98.3%) |
Target vessel, no. (%)
• Left anterior descending
• Left circumflex
• Right coronary artery |
31 (73.8%)
6 (14.3%)
5 (11.9%) |
35 (58.3%)
14 (23.3%)
11 (18.3%) |
21 (61.8%)
9 (26.5%)
4 (11.8%) |
32 (53.3%)
10 (16.7%)
18 (30.0%) |
33 (82.5%)
5 (12.5%)
2 (5.0%) |
29 (48.3%)
13 (21.7%)
18 (30.0%) |
AHA/ ACC lesion classification, no. (%)
• A
• B1
• B2
• C |
0 (0%)
19 (45.2%)
23 (54.8%)
0 (%) |
3 (5.0%)
29 (48.3%)
26 (43.3%)
2 (3.3%) |
0 (0%)
19 (55.9%)
15 (44.1%)
0 (%) |
4 (6.7%)
34 (56.7%)
21 (35.0%)
1 (1.7%) |
0 (0%)
25 (62.5%)
15 (37.5%)
0 (0%) |
4 (6.7%)
31 (51.7%)
23 (38.3%)
2 (3.3%) |
| Pre-procedure SYNTAX score, <22 only |
16.5±8.2 |
18.5±5.2 |
15.8±6.1 |
16.5±6.5 |
15.8±5.4 |
15.9±8.2 |
| Mean diameter of reference vessel, mm |
2.62±0.64 |
2.68±0.51 |
2.61±0.37 |
2.61±0.69 |
2.73±0.85 |
2.74±0.45 |
| Minimal lumen diameter (MLD), mm |
1.11±0.32 |
1.12±0.38 |
1.06±0.29 |
1.08±0.44 |
1.06±0.28 |
1.06±0.24 |
| Maximal lumen diameter, mm |
1.58±0.69 |
1.62±0.92 |
1.43±0.78 |
1.55±0.82 |
1.64±0.65 |
1.62±0.47 |
| Mean lumen diameter, mm |
1.32±0.74 |
1.35±0.81 |
1.28±0.66 |
1.29±0.78 |
1.39±0.71 |
1.40±0.69 |
| Diameter stenosis, % |
67.2±15.3 |
68.1±14.3 |
69.5±12.7 |
65.3±19.6 |
70.2±12.4 |
71.4±18.4 |
| Lesion length, mm |
8.22±2.16 |
8.12±4.68 |
8.94±4.82 |
9.03±5.26 |
8.74±4.04 |
8.85±3.92 |
| Plaque burden (percent atheroma volume, PAV), % |
69.3±16.5 |
68.5±12.3 |
69.9±14.6 |
69.4±12.2 |
70.8±15.2 |
68.4±14.4 |
| Total plaque-media volume (total atheroma volume – TAV), mm3 |
179.2±81.3 |
178.4±85.7 |
182.6±78.5 |
183.1±96.1 |
184.2±62.8 |
175.8±94.4 |
| Lumen volume, mm3 |
79.4±33.5 |
82.1±34.5 |
78.5±42.5 |
80.6±39.9 |
75.8±36.5 |
81.4±42.7 |
VH-IVUS:
• Dense calcium, %
• Necrotic core, %
• Fibrous tissue, %
• Fibro-fatty, % |
7.19±5.43
18.65±7.26
58.65±14.22
15.51±7.23 |
7.54±5.11
18.85±8.13
58.09±15.36
15.52±8.46 |
8.35±6.14
17.83±9.13
58.47±14.26
15.35±6.61 |
8.75±6.13
17.94±8.14
58.21±16.92
15.09±7.37 |
8.76±8.72
18.20±8.58
59.33±16.85
13.71±8.47 |
8.89±9.02
18.22±9.25
59.11±18.92
13.78±9.56 |
VH-IVUS:
• Dense calcium, mm2
• Necrotic core, mm2
• Fibrous tissue, mm2
• Fibro-fatty, mm2 |
0.32±0.30
0.83±0.69
2.61±1.22
0.69±0.48 |
0.34±0.32
0.85±0.64
2.62±1.38
0.70±0.49 |
0.37±0.32
0.79±0.66
2.59±1.34
0.68±0.43 |
0.40±0.36
0.82±0.79
2.66±1.42
0.69±0.48 |
0.39±0.39
0.81±0.64
2.64±1.37
0.61±0.55 |
0.40±0.36
0.82±0.79
2.66±1.42
0.62±0.46 |
Data are mean (SD) or number (%). CCS = Canadian Cardiovascular Society classification of angina pectoris. AHA/ACC = American Heart Association/ American College of Cardiology. Difference between groups and subsets is non-significant. Continuous variables are expressed as mean ± SD (standard deviation)